

Central Nervous System Disease Programs

Indication	Program	Preclinical	IND	Phase 1	Phase 2	Phase 3	NDA/BLA	Commercial	Brii Rights	Partners
PPD	BRII-296								Global	Internally discovered
Anxiety & Depressive Disorder	BRII-297								Global	Internally discovered

* Greater China – Mainland China, Macau, Hong Kong and Taiwan

(1) The Phase 2 combination clinical trials conducted by Brii Bio:

- Elebsiran + BRII-179
- BRII-179 + PEG-IFN α
- ENSURE: Elebsiran \pm PEG-IFN α

(2) Elebsiran was previously known as BRII-835 or VIR-2218.

(3) Tobeivart was previously known as BRII-877 or VIR-3434. The Phase 2 clinical trials have been conducted by Vir.

(4) VBI launched PreHevbrio/PreHevbri in the United States, Canada, European Union, European Economic Area, the United Kingdom, and Israel. Brii Bio acquired exclusive rights for APAC countries (ex-Japan) in July 2023.

(5) Epetraborole is also known as BRII-658. To this date, the development and clinical trials have been conducted by AN2.

Board of Directors

	Audit and Risk Committee	Nomination Committee	Remuneration Committee	Strategic Committee	Executive Directors	Non-executive Directors	Independent Non-executive Directors
Dr. Zhi Hong							
Dr. Ankang Li							
Dr. Martin J. Murphy Jr.							
Ms. Grace Hui Tang							
Mr. Yiu Wa Alec Tsui							
Mr. Gregg Huber Alton							
Dr. Taiyin Yang							

Chairperson Member

[CVs of the Board Members](#)

Corporate Executive Team





Susannah Cantrell, Ph.D.

Chief Business Officer



Eleanor (Ellee) de Groot, Ph.D.

Chief Technology Officer



Zhi Hong, Ph.D.

Executive Director
Chairman of the Board and
Chief Executive Officer



Brian Alvin Johns, Ph.D.

Chief Scientific Officer



Ankang Li, Ph.D., J.D., CFA

Executive Director, Chief
Strategy and Financial Officer
Chief Executive Officer of TSB
Therapeutics



David Margolis, M.D., MPH

Chief Medical Officer



Karen D. Neuendorff

Chief People Officer and Head
of Human Resources



Qing Zhu, Ph.D.

Head of China R&D


[CVs of the Corporate Executive Team Members](#)

Financial Highlights


BRII-B (RMB'000)	2021	2022	2023
Operating Results			
Other income	99,032	107,857	163,728
Other gains and losses	45,062	(12,289)	252,402
Research and development expenses	(494,615)	(440,634)	(402,705)
Administrative expenses	(208,404)	(168,629)	(196,499)
Fair value loss on financial liabilities at FVTPL	(3,598,847)	-	-
Finance costs	(1,175)	(851)	(494)
Listing expenses	(32,137)	-	-
Loss for the year	(4,191,084)	(489,781)	(184,370)
Financial Position			
Total assets	3,611,699	3,391,849	3,198,251

Total liabilities	300,443	234,352	125,869
Total equity (deficits)	3,311,256	3,157,497	3,072,382
Selected Items from Consolidated Cash Flow Statement			
Net cash used in operating activities	(879,457)	(496,279)	(594,014)
Net cash used in investing activities	(475,756)	(1,433,168)	(104,350)
Net cash from financing activities	3,230,134	(3,042)	(10,977)
Net increase in cash and cash equivalents	1,874,921	(1,932,489)	(709,341)
Cash and cash equivalents at end of the year	2,855,093	1,190,572	489,650
Key indicators			
Loss per share - Basic and diluted (RMB)	(9.48)	(0.67)	(0.24)
Current Ratio	1.22	1.34	2.21


Research and Development Expenses



Total Assets



Total Liabilities



Brii Biosciences Limited

U.S. OFFICES

Durham, NC, United States
WeWork, Suite 05-110, One City Center, 110
Corcoran Street, Durham, NC 27701, United States

San Mateo, CA, United States
WeWork, Suite 02-114, 1825 South Grant Street, San
Mateo, CA 94402, United States

Email: ir@briibio.com

CHINA OFFICES

Beijing, China
3rd Floor, Building #7, Zhongguancun, Dongsheng
International Science Park, No. 1 North
Yongtaizhuang Road, Haidian District, Beijing
100192, P.R.China

Shanghai, China
Room 805, 8th Floor, Kerry Parkside, No.1155
Fangdian Road, Pudong, District, Shanghai 201204,
P.R.China



Supplied by © EUROLAND IR®
For terms of use and data vendors information,
see [Disclaimer](#) | [Cookie policy](#)